Compare Global X Lithium & Battery Tech ETF (LIT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Lithium & Battery Tech ETF vs ResMed Inc. — how do they compare? Global X Lithium & Battery Tech ETF trades at $69.72 (market cap $1.45B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 22× Global X Lithium & Battery Tech ETF's market cap, and ResMed Inc. pays a 1.16% dividend while Global X Lithium & Battery Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Lithium & Battery Tech ETF for 56 Days and ResMed Inc. for 51 Days on average.
| LIT | RMD | |
|---|---|---|
Market Cap | $1.45B | $31.89B |
Volume | 89,392 | 618,314 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $91.62 | $277.88 |
52-Week Low | $53.92 | $182.82 |
Typical Hold Time | 56 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LIT (Global X Lithium & Battery Tech ETF) trades at $69.51, down 2.2% with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. Recent news highlights significant short interest decline (53.1% drop in September 2026) and positive catalysts from EV adoption trends. The ETF's performance reflects ongoing volatility in lithium markets amid shifting commodity prices and global electrification policies.
Outlook remains driven by long-term EV growth, though near-term risks include lithium price volatility and geopolitical tensions. Investment opportunity lies in exposure to battery technology leaders, balanced by sector-specific supply chain and regulatory uncertainties that could impact shareholder returns.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
